Beacon Investment Advisors LLC Sells 528 Shares of Kenvue Inc. (NYSE:KVUE)

Beacon Investment Advisors LLC cut its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,924 shares of the company’s stock after selling 528 shares during the period. Beacon Investment Advisors LLC’s holdings in Kenvue were worth $361,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new position in shares of Kenvue during the 4th quarter valued at $521,348,000. Franklin Resources Inc. grew its stake in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Boston Partners boosted its holdings in shares of Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock worth $503,145,000 after buying an additional 6,366,097 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Kenvue during the fourth quarter valued at about $98,926,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on KVUE shares. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Redburn Atlantic initiated coverage on Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. Piper Sandler upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Barclays lowered their target price on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, April 14th. Finally, Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $24.42.

Kenvue Price Performance

KVUE opened at $23.42 on Monday. The stock has a 50-day moving average price of $22.91 and a 200-day moving average price of $22.41. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market cap of $44.93 billion, a PE ratio of 44.19, a P/E/G ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.